Design Therapeutics(DSGN.US)

Last Updated 19:00:00 ET
longbridge loading

U.S. stock night trading volatility: Design Therapeutics fell 3.46% in after-hours trading, as positive news failed to counteract market sentiment fluctuations

Price Alert·
US
DSGN
-25.54%
Price Alert·
US
DSGN
-25.54%

Top 10 US Stock Losers (5.18)

Top Gainers&Losers·
US
DSGN
-25.54%
US
RXT
-17.53%
US
FCEL
-16.95%
Top Gainers&Losers·
US
DSGN
-25.54%
US
RXT
-17.53%
US
FCEL
-16.95%

Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% Upside

TradingView·
US
DSGN
-25.54%
US
PBE
-0.58%
US
FBT
-0.66%
TradingView·
US
DSGN
-25.54%
US
PBE
-0.58%
US
FBT
-0.66%

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

Unusual Whales·
US
DSGN
-25.54%
US
XBI
-2.31%
US
LABU
-6.92%
Unusual Whales·
US
DSGN
-25.54%
US
XBI
-2.31%
US
LABU
-6.92%

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026 | DSGN Stock News

StockTitan·
US
DSGN
-25.54%
US
FBT
-0.66%
US
BBH
-1.03%
StockTitan·
US
DSGN
-25.54%
US
FBT
-0.66%
US
BBH
-1.03%
© 2026 Longbridge｜Disclaimer